Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | MAPK14 | Q16539 | 9/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.36 |
| ▸ | ESR1 | P03372 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30680206 | 1.00 | LMNA (0.45) | LMNAMAPK14ALDH1A1SMN1; SMN2SLC29A1 | |
| SCHEMBL8166 | 0.89 | ADORA2A (0.47) | LMNAMAPK14ALDH1A1SMN1; SMN2 | |
| SCHEMBL30670890 | 0.89 | ADORA2A (0.47) | LMNAMAPK14ALDH1A1SMN1; SMN2 | |
| SCHEMBL8577 | 0.81 | ADORA2A (0.53) | LMNAALDH1A1SMN1; SMN2 | |
| SCHEMBL8786 | 0.81 | MEN1 (0.41) | LMNAALDH1A1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL29651680 | 0.81 | ADORA2A (0.53) | LMNAALDH1A1SMN1; SMN2 | |
| SCHEMBL8426 | 0.80 | PIK3CD (0.46) | LMNA | |
| SCHEMBL30013691 | 0.80 | PIK3CD (0.46) | LMNA | |
| SCHEMBL8117 | 0.79 | ADORA2A (0.49) | LMNAMAPK14SMN1; SMN2 | |
| SCHEMBL8903 | 0.78 | ADORA2A (0.49) | LMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4292596-A1 | METHOD AND COMBINATION FOR TREATING TUMORS | Curon Biopharmaceutical (Shanghai) Co., Limited (CN) | 2023-12-20 | — | — | EP | claimed |
| EP-2496567-A2 | NOVEL BENZOPYRAN KINASE MODULATORS | Rhizen Pharmaceuticals S.A. (CH) | 2012-09-12 | — | — | EP | claimed |
| WO-2011055215-A2 | NOVEL KINASE MODULATORS | INCOZEN THERAPEUTICS PVT. LTD. (IN) | 2011-05-12 | — | — | WO | claimed |
| US-20240139198-A1 | METHOD AND COMBINATION FOR TREATING TUMORS | CURON BIOPHARMACEUTICAL (SHANGHAI) CO., LIMITED (CN) | 2024-05-02 | — | — | US | disclosed |
| EP-4292596-A1 | METHOD AND COMBINATION FOR TREATING TUMORS | Curon Biopharmaceutical (Shanghai) Co., Limited (CN) | 2023-12-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240139198-A1 | METHOD AND COMBINATION FOR TREATING TUMORS | PDCD1, PDCD1LG2, CD274 | LMNA 3365/4885MAPK14 1838/4885ALDH1A1 3702/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.